RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target

Bicycle Therapeutics Limited +3.85%

Bicycle Therapeutics Limited

BCYC

19.95

+3.85%

RBC Capital analyst Gregory Renza reiterates Bicycle Therapeutics (NASDAQ: BCYC) with a Outperform and maintains $35 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via